Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to fundamentally change the way acute pain, chronic pain, and pruritus are managed. The Company aim to achieve this by developing new products that selectively target the body’s peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the undesirable side effects typically associated with currently available pain and itch therapeutics.

TypePublic
HQStamford, US
Founded2004
Size (employees)34 (est)
Websitecaratherapeutics.com
Cara Therapeutics was founded in 2004 and is headquartered in Stamford, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Cara Therapeutics Office Locations

Cara Therapeutics has an office in Stamford
Stamford, US (HQ)
4 Stamford Plz
Show all (1)
Report incorrect company information

Cara Therapeutics Financials and Metrics

Cara Therapeutics Revenue

Cara Therapeutics's revenue was reported to be $911 k in FY, 2017 which is a 959.3% increase from the previous period.
USD

Revenue (Q2, 2018)

2.9 m

Net income (Q2, 2018)

(34 m)

EBIT (Q2, 2018)

(34.9 m)

Market capitalization (20-Sep-2018)

939.8 m

Closing stock price (20-Sep-2018)

23.9

Cash (30-Jun-2018)

17.8 m
Cara Therapeutics's current market capitalization is $939.8 m.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

3.8 m86 k911 k

Revenue growth, %

(98%)959%

General and administrative expense

7.8 m9.2 m11.9 m

R&D expense

21.2 m49.3 m48.5 m
Quarterly
USDQ1, 2018Q2, 2018

Revenue

2.9 m

General and administrative expense

3.7 m7.4 m

R&D expense

13.4 m30.4 m

Operating expense total

17.1 m37.8 m
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

15.1 m12.1 m9.4 m

Prepaid Expenses

1.7 m1.5 m1.6 m

Current Assets

108.9 m61.4 m95.1 m

PP&E

1.3 m1.6 m1.2 m
Quarterly
USDQ1, 2018Q2, 2018

Cash

11.9 m17.8 m

Current Assets

78.8 m138.5 m

PP&E

1.1 m959 k

Total Assets

80.6 m139.9 m
USDFY, 2015FY, 2016FY, 2017

Net Income

24.7 m(57.3 m)(58.1 m)

Depreciation and Amortization

839 k1.5 m495 k

Cash From Operating Activities

(21.5 m)(47.4 m)(54.8 m)

Purchases of PP&E

(20 k)(717 k)(58 k)
USDY, 2018

Financial Leverage

1.9 x
Show all financial metrics
Report incorrect company information

Cara Therapeutics News and Updates

Cara Therapeutics to Present at the 27th European Academy of Dermatology & Venereology Congress

STAMFORD, Conn., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced…
Show more
Report incorrect company information

Cara Therapeutics Company Life and Culture

Report incorrect company information